Depomed files patent infringement suits relating to Gralise

5 March 2012

California, USA-based Depomed (Nasdaq: DEPO) yesterday filed a patent infringement law suit in the US District Court for the District of New Jersey against three companies that have filed Abbreviated New Drug Applications with the Food and Drug Administration to market generic Gralise (gabapentin).

The drug is Depomed's once-daily gabapentin product for the management of post-herpetic neuralgia, or shingles, for which it regained marketing rights a year ago from Abbott Laboratories (The Pharma Letter March 18, 2011) and launched in the USA last October.

The law suit claims infringement of Depomed's six US patents listed for Gralise in the FDA's Orange Book, the last of which expires in 2024, by each defendant's proposed generic product. The defendants in the law suit are: Iceland-headquartered Actavis Elizabeth and an affiliated company; Watson Laboratories and affiliated companies; and Incepta Pharmaceuticals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK